Evolving Landscape of Chronic GVHD Management: From Diagnosis to Novel Therapies

home / expert-perspective-tumor-board / evolving-landscape-of-chronic-gvhd-management-from-diagnosis-to-novel-therapies

Yi Bin Chen, MD; Corey Cutler, MD; Sami Brake, MD, and Colleen Danielson, NP, explore the multifaceted aspects of chronic graft-versus-host disease (cGVHD), from its impact on patient quality of life and diagnostic criteria to treatment strategies across multiple lines of therapy, including ruxolitinib, belumosudil, and axatilimab, while addressing clinical considerations and safety profiles.

4 KOLs are featured in this series.

EP. 1: Chronic GVHD and Patient Quality of Life: Multisystem Effects and Functional Impairments

Yi-Bin Chen, MD;Corey S. Cutler, MD, MPH, FRCPC;Sami Brake, MD;Colleen Danielson, NP
September 3rd 2024

Panelists discuss how chronic graft-versus-host disease manifests across multiple organ systems and the diagnostic criteria used to identify and assess its various presentations.

Watch

4 KOLs are featured in this series.

EP. 2: Multisystem cGVHD Manifestations: A Case Study with NIH Organ-Specific Scoring

Yi-Bin Chen, MD;Corey S. Cutler, MD, MPH, FRCPC;Sami Brake, MD;Colleen Danielson, NP
September 10th 2024

Panelists discuss how a case study illustrates the multisystem manifestations of chronic graft-versus-host disease and demonstrate the application of NIH organ-specific scoring for comprehensive assessment.

Watch

4 KOLs are featured in this series.

EP. 3: Stratifying cGVHD Severity and Tailoring Therapy: Systemic Treatments and Supportive Care

Yi-Bin Chen, MD;Corey S. Cutler, MD, MPH, FRCPC;Sami Brake, MD;Colleen Danielson, NP
September 10th 2024

Panelists discuss how chronic graft-versus-host disease severity can be stratified to guide the tailoring of systemic treatments and supportive care strategies for optimal patient management.

Watch

4 KOLs are featured in this series.

EP. 4: Second-Line Strategies in cGVHD: Efficacy Data with Ruxolitinib

Yi-Bin Chen, MD;Corey S. Cutler, MD, MPH, FRCPC;Sami Brake, MD;Colleen Danielson, NP
September 17th 2024

Panelists discuss how ruxolitinib has demonstrated efficacy as a second-line treatment strategy for chronic graft-versus-host disease, reviewing the available data on its effectiveness.

Watch

4 KOLs are featured in this series.

EP. 5: Navigating the Safety Profile of Ruxolitinib in cGVHD

Yi-Bin Chen, MD;Corey S. Cutler, MD, MPH, FRCPC;Sami Brake, MD;Colleen Danielson, NP
September 17th 2024

Panelists discuss how to effectively manage the safety profile of ruxolitinib when used in the treatment of chronic graft-versus-host disease, addressing potential adverse effects and monitoring strategies.

Watch